BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35362856)

  • 41. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alzheimer's disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment.
    Xue YY; Chen YH; Lin RR; Huang HF; Wu ZY; Tao QQ;
    Neurosci Lett; 2022 Feb; 771():136419. PubMed ID: 34958910
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CSF p-tau/Aβ
    Santangelo R; Masserini F; Agosta F; Sala A; Caminiti SP; Cecchetti G; Caso F; Martinelli V; Pinto P; Passerini G; Perani D; Magnani G; Filippi M
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3152-3164. PubMed ID: 32415550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Individual brain metabolic connectome indicator based on Kullback-Leibler Divergence Similarity Estimation predicts progression from mild cognitive impairment to Alzheimer's dementia.
    Wang M; Jiang J; Yan Z; Alberts I; Ge J; Zhang H; Zuo C; Yu J; Rominger A; Shi K;
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2753-2764. PubMed ID: 32318784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study.
    Teng L; Li Y; Zhao Y; Hu T; Zhang Z; Yao Z; Hu B;
    BMC Neurol; 2020 Apr; 20(1):148. PubMed ID: 32316912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
    Vasanthakumar A; Davis JW; Idler K; Waring JF; Asque E; Riley-Gillis B; Grosskurth S; Srivastava G; Kim S; Nho K; Nudelman KNH; Faber K; Sun Y; Foroud TM; Estrada K; Apostolova LG; Li QS; Saykin AJ;
    Clin Epigenetics; 2020 Jun; 12(1):84. PubMed ID: 32539856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Choroid plexus volumes and auditory verbal learning scores are associated with conversion from mild cognitive impairment to Alzheimer's disease.
    Pearson MJ; Wagstaff R; Williams RJ;
    Brain Behav; 2024 Jul; 14(7):e3611. PubMed ID: 38956818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.
    Willette AA; Calhoun VD; Egan JM; Kapogiannis D;
    Psychiatry Res; 2014 Nov; 224(2):81-8. PubMed ID: 25194437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Transition of Mild Cognitive Impairment Over Time: An AV45- and FDG-PET Study of Reversion and Conversion Phenomena.
    Ashraf-Ganjouei A; Moradi K; Faghani S; Abdolalizadeh A; Khomeijani-Farahani M; Fatehi F; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2021; 18(9):721-731. PubMed ID: 34819007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
    Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
    Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.